3B BlackBio Dx: consol. revenue up 42% YoY, but margin dilution caps PAT growth at 20%
PAT +19.85% YoY · revenue +42.41% · margins compressing
₹48.28 Cr
+42.41% YoY
₹18.02 Cr
+19.85% YoY
34.01%
-4.1pp YoY
₹21.03
3B BlackBio Dx Ltd (formerly Kilpest India), reporting on a consolidated basis, posted Q2 FY27 revenue of ₹48.28 Cr, up 42.4% YoY from ₹33.90 Cr and 44.2% QoQ from ₹33.49 Cr — comfortably ahead of management's FY27 guidance of 15-20% consolidated revenue growth, with H1 FY27 revenue of ₹81.77 Cr already up 45.7% YoY. Consolidated PAT came in at ₹18.02 Cr (owners' share ₹17.80 Cr), up 19.9% YoY from ₹15.04 Cr, with basic EPS of ₹21.03 versus ₹17.55 a year ago. No exceptional items appear in either period, so the comparison is clean.
Q2 FY-2027 vs prior quarters
The gap between 42% revenue growth and 20% profit growth shows up squarely in margins: consolidated NPM (PAT/total income) compressed to 34.0% from 38.2% a year ago, even as OPM (revenue less material, employee and other operating costs, before interest and depreciation) held roughly flat at 43.6% versus 43.5%. The compression is better explained via H1 EBITDA, which grew only ~11.4% YoY — short of the "similar trajectory" to revenue (15-20%) management guided for EBITDA alongside the top line in the June 2026 concall. Standalone (the core agrochemical and diagnostics business) grew revenue 30.8% YoY to ₹36.51 Cr and PAT 20.2% YoY to ₹17.96 Cr — slower on revenue than the consolidated print, confirming the overseas subsidiaries are adding the incremental growth at a cost structure that dilutes group margins.
The stock went into the print at ₹1,342, down 7.5% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Management is guiding for a consolidated revenue growth of 15% to 20% in FY27, with a similar trajectory expected for EBITDA growth. The company anticipates Coris BioConcept to contribute approximately INR50 crores to INR52 crores in revenue with a slight EBITDA positive contribution, while the core 3B and TRUPCR Europ
— This quarter: beat
Coris BioConcept was guided to add ~₹50-52 Cr of FY27 revenue with a slight positive EBITDA contribution; the consolidated-minus-standalone revenue gap of ~₹22.3 Cr in H1 FY27 puts the subsidiaries on a run-rate below that full-year guide unless H2 scales up materially. Minority interest also swung from a ₹0.55 Cr loss attributable to non-controlling interests in Q1 FY27 to a ₹0.23 Cr profit in Q2, pointing to volatility at the overseas units. A web search turned up no analyst consensus or brokerage preview specific to this quarter, so vsStreet is unknown; the exchange filing carried no separate management press release beyond the standard notes, which flag that the agrochemical business is seasonal — Q2 (Jul-Sep, kharif season) is typically its strongest quarter, which is why the QoQ PAT jump (+100.8%, to ₹18.02 Cr from ₹8.98 Cr) should be read as a seasonal effect rather than a trend signal.
W1
EBITDA growth (H1 FY27: +11.4% YoY) needs to re-accelerate toward the guided 15-20% trajectory, or further NPM compression is likely.
W2
Coris BioConcept/TRUPCR Europe revenue run-rate (~₹22.3 Cr in H1 FY27) versus the ₹50-52 Cr full-year guide for Coris alone — H2 contribution is the checkpoint.
W3
Minority-interest swings (-₹0.55 Cr in Q1 FY27 vs +₹0.23 Cr in Q2) — watch whether overseas subsidiary profitability stabilizes.